Anton Henssen

So nice to see our work out in print! Very special to have two of our eDyNAmiC papers in the same issue. What a beautiful cover! Thank you @elizsmckenna.bsky.social !! @aacrjournals.bsky.social

Thank you for inviting me to talk alongside Ido about our work on ecDNA!

Now online in Cancer Discovery @aacrjournals.bsky.social: Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers - by Giulia Montuori, Fengyu Tu, anton-henssen.bsky.social, Jan Dörr, and colleagues doi.org/10.1158/2159...

A huge thank you to all #IEAwards25 winners and nominees for an inspiring evening. We can’t wait to see what’s next on your horizon.

Read more: bit.ly/44m94a0

#OnMyHorizon @anton-henssen.bsky.social, @nnennayakanu.bsky.social, @michellecruk.bsky.social @timwitney.bsky.social, @cuh.nhs.uk

I am excited, our collaborative work on tumours driven by ecDNA amplified MYCN and the underlying copy-number dependent fitness landscape just came out in Cancer Discovery @aacrjournals.bsky.social.

@anton-henssen.bsky.social @cancergrand.bsky.social

aacrjournals.org/cancerdiscov...

@anton-henssen.bsky.social we are looking forward to your presentation at #ecDNA25 in Mexico! Please share with your followers to let them know our early bird registration & talk submission close on 02 June 2025!
💰Grants available
✅More info: bit.ly/42XY0za

🚨🚨Paper out! 🚨🚨

Delighted to share our work, now published in ‪@natgenet.nature.com‬ 🧬!
shorturl.at/94s5S

We identified a targetable, chromothripsis-associated genetic event in blast phase (BP) MPN, a particularly poor prognostic subtype of acute leukaemia. 1/n

Illustration: Hratch Arbach
🧵👇

Congrats Juliane and Monika authors.elsevier.com/sd/article/S...

New @theaacr.bsky.social Cancer Discovery paper on ecDNA in urothelial carcinoma reveals how ecDNAs:
💡 Drive #BladderCancer evolution
💡 Promote immune evasion
💡 Amplify oncogenes
💡 Fuel tumour heterogeneity
💡 May be a biomarker in urine for non-invasive detection
aacrjournals.org/cancerdiscov...

Great conference ! I look forward to attending. 🔥🔥👇🏻👇🏻

Congrats !! Great work

Exciting new paper 🔥🔥👇🏻👇🏻

Great conference with expert lineup ! I look forward to attending! 🔥🔥👇🏻👇🏻

It was a pleasure reviewing this article ! 👏🏻👏🏻

Complex rearrangements fuel ER+ and HER2+ breast tumours - Nature A study identifies three dominant genomic archetypes of breast cancer induced by discrete mutational processes, describing a continuum of genomic profiles and detailing the mechanisms underlying the p...

The Curtis Lab’s latest study on the genomic architecture of breast cancer from the pre-invasive to metastatic setting is now out in Nature! www.nature.com/articles/s41...

👏🏻👏🏻👏🏻👏🏻

Rare germline structural variants increase risk for pediatric solid tumors Pediatric solid tumors are a leading cause of childhood disease mortality. In this work, we examined germline structural variants (SVs) as risk factors for pediatric extracranial solid tumors using ge...

Here's our latest, led by Drs. Riaz Gillani & Ryan Collins - we studied a type of inherited genetic event (structural variants) + risk of developing certain cancers in kids:
@danafarber.bsky.social @bostonchildrens.bsky.social @broadinstitute.org @science.org

www.science.org/doi/10.1126/...

🔥🔥👇🏻👇🏻

🔥🔥👇🏻👇🏻

Important work by Heribert Jürgens and colleagues on how telemedicine can improve the management of patients suffering from sarcoma. 👏🏻👏🏻👇🏻👇🏻

www.sciencedirect.com/science/arti...

80%

Congrats !! Such a great achievement ! 👏🏻👏🏻🔥🔥

Major milestone in ecDNA research!!! 👏🏻👏🏻👏🏻🔥🔥🔥👇🏻👇🏻

1/ In two back-to-back papers, we present our de novo TRACeR platform for targeting MHC-I and MHC-II antigens

TRACeR for MHC-I: go.nature.com/4gcLzn5
TRACeR for MHC-II: go.nature.com/4gj5OQk

Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia Understanding the molecular pathogenesis of MLL fusion oncoprotein (MLL-FP) leukaemia has spawned epigenetic therapies that have improved clinical outcomes in this often-incurable disease. Using genet...

Thrilled to share a wonderful collaboration with Scott Armstrong, Florian Perner & Shellaina Gordon - exciting times ahead!

www.biorxiv.org/content/10.1...

Fantastic episode!! 👏🏻👏🏻

👏🏻👏🏻

Targeting RNA and Protein Turnover in Aneuploid Cancers Summary:. Aneuploidy, an imbalance in chromosome number, is a hallmark of human cancers with chromosomal instability, and it remains a major therapeutic challenge. In this issue, Ippolito and colleagu...

Great to see our joint study with @stesantaguida.bsky.social published in this month’s issue of Cancer Discovery:
aacrjournals.org/cancerdiscov...

With a super-kind Research Highlight written by Sam Bakhoum:

I generally agree with you , but I also find the overheads in the US quite high compared to other countries. In Germany the DFG pays around 20% overhead. Why are overheads so much higher in the US ?

👏🏻👏🏻👏🏻🔥🔥👇🏻👇🏻